Understanding Subcutaneous Tissue Pressure for Engineering Injection Devices for Large-Volume Protein Delivery

被引:46
作者
Doughty, Diane V. [1 ]
Clawson, Corbin Z. [1 ]
Lambert, William [1 ]
Subramony, J. Anand [1 ]
机构
[1] MedImmune LLC, Biopharmaceut Dev, Drug Delivery & Device Dev, Gaithersburg, MD 20878 USA
关键词
skin; injectables; injectors; physiological model; biocompatibility; monoclonal antibody; subcutaneous; parenteral; device; pain; IMMUNOGLOBULIN REPLACEMENT; MONOCLONAL-ANTIBODY; PREFILLED SYRINGE; PAIN; THERAPY; PHARMACOKINETICS; TRASTUZUMAB; CHALLENGES; TOXICOLOGY; DURATION;
D O I
10.1016/j.xphs.2016.04.009
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Subcutaneous injection allows for self-administration of monoclonal antibodies using prefilled syringes, autoinjectors, and on-body injector devices. However, subcutaneous injections are typically limited to 1 mL due to concerns of injection pain from volume, viscosity, and formulation characteristics. Back pressure can serve as an indicator for changes in subcutaneous mechanical properties leading to pain during injection. The purpose of this study was to investigate subcutaneous pressures and injection site reactions as a function of injection volume and flow rate. A pressure sensor in the fluid path recorded subcutaneous pressures in the abdomen of Yorkshire swine. The subcutaneous tissue accommodates large-volume injections and with little back pressure as long as low flow rates are used. A 1 mL injection in 10 seconds (360 mL/h flow rate) generated a pressure of 24.0 +/- 3.4 kPa, whereas 10 mL delivered in 10 minutes (60 mL/h flow rate) generated a pressure of 7.4 +/- 7.8 kPa. After the injection, the pressure decays to 0 over several seconds. The subcutaneous pressures and mechanical strain increased with increasing flow rate but not increasing dose volume. These data are useful for the design of injection devices to mitigate back pressure and pain during subcutaneous large-volume injection. (C) 2016 American Pharmacists Association (R). Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:2105 / 2113
页数:9
相关论文
共 45 条
[21]   Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial [J].
Ismael, Gustavo ;
Hegg, Roberto ;
Muehlbauer, Susanne ;
Heinzmann, Dominik ;
Lum, Bert ;
Kim, Sung-Bae ;
Pienkowski, Tadeusz ;
Lichinitser, Mikhail ;
Semiglazov, Vladimir ;
Melichar, Bohuslav ;
Jackisch, Christian .
LANCET ONCOLOGY, 2012, 13 (09) :869-878
[22]   Subcutaneous immunoglobulin replacement therapy with Hizentra®, the first 20% SCIG preparation: a Practical approach [J].
Jolles, S. ;
Sleasman, J. W. .
ADVANCES IN THERAPY, 2011, 28 (07) :521-533
[23]   Pain assessment of subcutaneous injections [J].
Jorgensen, JT ;
Romsing, J ;
Rasmussen, M ;
MollerSonnergaard, J ;
Vang, L ;
Musaeus, L .
ANNALS OF PHARMACOTHERAPY, 1996, 30 (7-8) :729-732
[24]  
Justad Mindy, 2009, Home Healthc Nurse, V27, P140, DOI 10.1097/01.NHH.0000347677.15617.ff
[25]   Subcutaneous Absorption of Monoclonal Antibodies: Role of Dose, Site of Injection, and Injection Volume on Rituximab Pharmacokinetics in Rats [J].
Kagan, Leonid ;
Turner, Michael R. ;
Balu-Iyer, Sathy V. ;
Mager, Donald E. .
PHARMACEUTICAL RESEARCH, 2012, 29 (02) :490-499
[26]   Porcine model to evaluate local tissue tolerability associated with subcutaneous delivery of protein [J].
Kang, D. W. ;
Oh, D. A. ;
Fu, G. Y. ;
Anderson, J. M. ;
Zepeda, M. L. .
JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, 2013, 67 (03) :140-147
[27]   Improving the outcomes of biopharmaceutical delivery via the subcutaneous route by understanding the chemical, physical and physiological properties of the subcutaneous injection site [J].
Kinnunen, Hanne M. ;
Mrsny, Randall J. .
JOURNAL OF CONTROLLED RELEASE, 2014, 182 :22-32
[28]   Reversible self-association increases the viscosity of a concentrated monoclonal antibody in aqueous solution [J].
Liu, J ;
Nguyen, MDH ;
Andya, JD ;
Shire, SJ .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2005, 94 (09) :1928-1940
[29]   Local tolerance and stability up to 24 months of a new 20% proline-stabilized polyclonal immunoglobulin for subcutaneous administration [J].
Maeder, Werner ;
Lieby, Patricia ;
Sebald, Andrea ;
Spycher, Martin ;
Pedrussio, Renzo ;
Bolli, Reinhard .
BIOLOGICALS, 2011, 39 (01) :43-49
[30]   Protein Aggregation: Pathways, Induction Factors and Analysis [J].
Mahler, Hanns-Christian ;
Friess, Wolfgang ;
Grauschopf, Ulla ;
Kiese, Sylvia .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2009, 98 (09) :2909-2934